Azithromycin for Reducing Infections During Labor

Overseen By Kristina Roloff, DO

Age: 18 - 65

Sex: Female

Trial Phase: Phase 1

Sponsor: Arrowhead Regional Medical Center

Must not be taking: Antibiotics, Antivirals

Disqualifiers: Active infection, Substance abuse, others

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: 1 day

400 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if azithromycin, a common antibiotic, can reduce infections for mothers and babies during labor. Participants will receive either azithromycin or a placebo (a harmless pill with no active medicine) before labor begins. Women in their third trimester with a single baby and planning to induce labor are eligible to join. The goal is to make childbirth safer by reducing infections. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot have used antibiotics or antiviral agents in the last 7 days before joining.

Is there any evidence suggesting that azithromycin is likely to be safe for humans?

Research has shown that azithromycin is generally safe for pregnant women. Previous studies found that it helps reduce infections in mothers and babies during childbirth. Common side effects include nausea, vomiting, and diarrhea, but these are usually mild and manageable. Past reports did not identify any serious safety issues when azithromycin was used in similar situations. This suggests that most people tolerate azithromycin well, and it effectively prevents infections during childbirth. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Azithromycin is unique because it targets bacterial infections during labor, a critical time when preventing infections is essential for the health of both mother and baby. Unlike standard antibiotics used in labor, which often require multiple doses, azithromycin is administered as a single, high-dose treatment, making it more convenient and potentially more effective in quickly reducing infection risk. Researchers are excited about azithromycin because of its broad-spectrum antibacterial properties and the potential to significantly lower infection rates with minimal intervention.

What evidence suggests that azithromycin might be an effective treatment for reducing infections during labor?

Research has shown that azithromycin, which participants in this trial may receive, effectively reduces infections in mothers during labor. One study found that women who received azithromycin had a 50% lower risk of developing inflammation of the uterus lining (endometritis) compared to those who didn't. Another study reported a 29% reduction in overall infections in mothers, including severe infections like sepsis, when azithromycin was used. Additionally, a combined analysis of multiple studies has confirmed that azithromycin helps lower the rates of sepsis and other infections during labor. These findings suggest that azithromycin could help keep mothers healthier during childbirth by reducing the risk of infections. ^{1 4 5 6 7}

Are You a Good Fit for This Trial?

This trial is for pregnant women in their third trimester (28 weeks or more) who are undergoing labor induction. Participants should be aged 18-45, have a single pregnancy with no complications that would prevent vaginal delivery, and can give informed consent. Women with recent antibiotic use, active infections, substance abuse issues, or inability to understand English or Spanish are excluded.

Inclusion Criteria

My labor was started by a doctor for health reasons or by choice after 39 weeks.

Reassuring fetal heart rate tracing

Singleton pregnancy

Exclusion Criteria

Does not read or write in English or Spanish

Active substance abuse

I am currently incarcerated.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Administration of 2 grams oral azithromycin or placebo prior to the start of induction of labor

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on reduction in maternal and neonatal infections

6 weeks postpartum

What Are the Treatments Tested in This Trial?

Interventions

• Azithromycin

Trial Overview

The study tests if taking a one-time dose of 2 grams of Azithromycin before inducing labor can reduce maternal and neonatal infections. It's a double-blind trial meaning neither the participants nor the researchers know who gets the real medicine versus a placebo.

How Is the Trial Designed?

Group I: Azithromycin Arm Active Control 1 Intervention

Administration of 2 grams oral azithromycin (4 tablets of 500 mg) prior to the start of induction , once.

Group II: Placebo Arm Placebo Group 2 Interventions

Administration of 4 magnesium oxide tablets prior to the start of induction , once.

Azithromycin is already approved in European Union, United States, Canada for the following indications:

Approved in European Union as Azithromycin for:

• Respiratory tract infections
• Skin and soft tissue infections
• Sexually transmitted diseases
• Toxoplasmosis
• Malaria
• Preterm prelabor rupture of membranes

Approved in United States as Azithromycin for:

• Respiratory tract infections
• Skin and soft tissue infections
• Sexually transmitted diseases
• Toxoplasmosis
• Malaria
• Preterm prelabor rupture of membranes

Approved in Canada as Azithromycin for:

• Respiratory tract infections
• Skin and soft tissue infections
• Sexually transmitted diseases
• Toxoplasmosis
• Malaria
• Preterm prelabor rupture of membranes

Who Is Running the Clinical Trial?

Arrowhead Regional Medical Center

Lead Sponsor

Trials

18

Recruited

28,200+

Published Research Related to This Trial

Azithromycin is an effective antimicrobial agent against common lower respiratory tract pathogens, showing superior activity against Haemophilus influenzae compared to other macrolides.

Clinical studies demonstrate that a short course of azithromycin (3 or 5 days) is as effective as a longer 10-day course of traditional antibiotics, which may improve patient compliance and reduce treatment duration.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Azithromycin in lower respiratory tract infections. Lode, H., Schaberg, T.[2013]

In a study of 60 pregnant women with preterm labor or PROM, a single dose of azithromycin did not significantly reduce colonization of Ureaplasma urealyticum compared to a placebo, with colonization rates remaining high in both groups.

Although azithromycin treatment showed a lower rate of vertical transmission of U. urealyticum (20% vs. 50% in controls), the overall ineffectiveness in reducing colonization suggests that azithromycin may not be a reliable treatment option for this condition.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. Ogasawara, KK., Goodwin, TM.[2008]

In a study involving 756 laboring women, a single dose of oral azithromycin, with or without amoxicillin, did not significantly reduce the rates of maternal peripartum or neonatal infections compared to a placebo.

However, the combination of azithromycin and amoxicillin did show a significant reduction in chorioamnionitis and wound infections compared to the placebo group, suggesting some targeted benefits despite the overall lack of effect on broader infection rates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single Dose of Oral Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection in Laboring, High-Risk Women in Cameroon: A Randomized Controlled Trial. Subramaniam, A., Ye, Y., Mbah, R., et al.[2023]

In a study of 254 women (127 receiving azithromycin and 127 controls), the addition of azithromycin to standard treatments for preterm labor did not significantly prolong pregnancy or improve gestational age outcomes.

Despite being used in a higher-risk population, the use of azithromycin showed no clear benefits compared to standard care, indicating that its efficacy in this context is questionable.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of Azithromycin on Pregnancy Prolongation in Women at Risk of Preterm Labor: A Time-to-Event Analysis. Goyer, I., Ferland, G., Ruo, N., et al.[2020]

Azithromycin is an effective broad-spectrum antibiotic with a long half-life and good tissue penetration, making it suitable for treating various infections, including respiratory and sexually transmitted infections.

While azithromycin has beneficial immunomodulatory effects for chronic respiratory diseases, it carries risks of serious side effects like cardiovascular arrhythmias and hearing loss, and there are concerns about macrolide resistance and drug interactions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prescribing azithromycin. McMullan, BJ., Mostaghim, M.[2023]

Azithromycin significantly reduces the risk of bronchopulmonary dysplasia (BPD) in extremely premature neonates, with a relative risk of 0.83 based on a review of 11 studies involving 473 neonates.

While azithromycin is associated with various adverse events, including respiratory and gastrointestinal issues, there was no significant increase in liver enzyme levels compared to placebo, indicating a relatively safe profile for this medication in neonates.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Use and safety of azithromycin in neonates: a systematic review. Smith, C., Egunsola, O., Choonara, I., et al.[2022]

A meta-analysis of nine studies involving 3,597 pediatric patients found that azithromycin has a statistically significant lower risk of adverse events compared to other antibiotics, indicating its relative safety in treating infectious diseases in children.

While azithromycin is generally safe, caution is advised with higher dosages, suggesting that careful monitoring is necessary to avoid potential side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis. Li, D., Wang, Y.[2022]

A large, multinational randomized trial is underway to evaluate whether a single oral dose of 2 g azithromycin given to women in labor can reduce maternal and neonatal sepsis and mortality, involving 34,000 participants across multiple regions.

This study aims to provide critical data on the efficacy of azithromycin in preventing infections during labor, which could significantly impact maternal and neonatal health outcomes in areas with high rates of infection-related deaths.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prevention of maternal and neonatal death/infections with a single oral dose of azithromycin in women in labour in low-income and middle-income countries (A-PLUS): a study protocol for a multinational, randomised placebo-controlled clinical trial. Hemingway-Foday, J., Tita, A., Chomba, E., et al.[2023]

Azithromycin is highly effective against a range of bacteria, including Staphylococcus aureus and Haemophilus influenzae, showing particularly strong activity against H. influenzae compared to other macrolides.

After oral administration, azithromycin is well-absorbed and distributed throughout the body, achieving higher concentrations in infected tissues due to its selective delivery by phagocytes, leading to successful treatment outcomes for respiratory infections with a convenient 3-day dosing regimen.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent]. Matsunaga, T.[2019]

In a study involving 29,278 women planning vaginal delivery, a single 2-g oral dose of azithromycin significantly reduced the risk of maternal sepsis or death compared to placebo (1.6% vs. 2.4%), indicating its efficacy in preventing maternal infections during labor.

However, azithromycin did not significantly impact the rates of stillbirth, neonatal death, or neonatal sepsis, suggesting that while it is beneficial for maternal health, it does not improve outcomes for newborns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth. Tita, ATN., Carlo, WA., McClure, EM., et al.[2023]

In a study of 3,995 patients aged 2-94, azithromycin demonstrated a favorable safety profile, with only 12.0% of patients experiencing side effects, which is significantly lower than the 14.2% seen with other standard antibiotics.

The most common side effects were mild to moderate gastrointestinal issues, and only 0.7% of patients discontinued treatment due to side effects, indicating that azithromycin is well tolerated even among patients with various concurrent illnesses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical toleration and safety of azithromycin. Hopkins, S.[2022]

In a study of 2,339 women undergoing cesarean delivery, adding azithromycin to standard preoperative antibiotics did not significantly reduce the overall rate of postoperative infections compared to standard prophylaxis alone.

The results suggest that while azithromycin may have benefits for certain groups (like women in labor), its effectiveness may be limited, especially for women not in labor, indicating that the practice change may not yield the expected benefits in all cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical effectiveness of adding azithromycin to antimicrobial prophylaxis for cesarean delivery. Pierce, SL., Bisson, CM., Dubois, ME., et al.[2022]

Citations

1.

thelancet.com

thelancet.com/journals/langlo/article/PIIS2214-109X(24)00562-X/fulltext

Effectiveness of intrapartum azithromycin to prevent ...

Our study showed that maternal infections of any type occurred less often in the azithromycin group compared with the placebo group, and that the effect was ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11950424/

Cost-effectiveness of intrapartum azithromycin to prevent ...

In 2023, the Azithromycin Prevention in Labor Use (A-PLUS) trial showed intrapartum azithromycin for women planning a vaginal birth reduced the ...

3.

nejm.org

nejm.org/doi/full/10.1056/NEJMoa2212111

Azithromycin to Prevent Sepsis or Death in Women ...

In the U.S. trial, the use of azithromycin resulted in a lower incidence of maternal infections (including a 50% lower risk of endometritis and ...

4.

bmcpregnancychildbirth.biomedcentral.com

bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-024-06390-6

Can the use of azithromycin during labour reduce the ...

In this meta-analysis, azithromycin use during labour reduced the incidence of maternal sepsis, endometritis, incisional infections and urinary tract ...

5.

fnih.org

fnih.org/news/antibiotic-cuts-maternal-infection-rates-globally-proves-cost-effective/

Antibiotic Cuts Maternal Infection Rates Globally, Proves ...

The results: Any maternal infection, including sepsis, occurred 29% less often when the drug was administered during labor compared to a placebo group. The ...

6.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11253273/

PeRinatal, neOnatal, and Maternal OuTcomEs with ...

Initial randomised controlled trials (RCTs) showed that prophylactic azithromycin in pregnant women improved maternal and neonatal outcomes; ...

7.

sciencedirect.com

sciencedirect.com/science/article/pii/S2214109X24005175

Cost-effectiveness of intrapartum azithromycin to prevent ...

In this cost-effectiveness analysis, overall results showed intrapartum azithromycin was associated with 1592·0 (95% CI 1139·7–2024·1) cases of infection, ...